Literature DB >> 872062

Effect of hyperthermia on malignant cells in vivo. A review and a hypothesis.

J Overgaard.   

Abstract

The relevant literature is reviewed in an attempt to clarify the mechanism of heat-dependent tumor cell destruction in vivo. Malignant cells in vivo appear to be selectively destroyed by hyperthermia in the range of 41-43 degrees C. Heat evidently affects nuclear function, expressed by an inhibited RNA, DNA and protein synthesis and characteristic arrest or delay of cells in certain locations of the cell cycle. However, as these effects appear to be reversible and are observed in normal cells as well as malignant cells, they probably do not explain the hyperthermic induced selective in vivo destruction of malignant cells. Heat-induced cytoplasmic damage appears to be of more importance. Increased lysosomal activation is observed, and is further intensified by a relatively increased anaerobic glycolysis which develops selectively in tumor cells. A hypothesis is proposed and discussed which explains the marked and selective in vivo tumor cell destruction as a consequence of the enhancing effect on the cytoplasmic damage of certain environmental factors (e.g. increased acidity, hypoxia and insufficient nutrition.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 872062     DOI: 10.1002/1097-0142(197706)39:6<2637::aid-cncr2820390650>3.0.co;2-s

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  48 in total

1.  Activity of the epidermal-growth-factor receptor and phospholipase C-gamma 1 in heat-stressed fibroblasts and A-431 cells.

Authors:  S M Liu; G Carpenter
Journal:  Biochem J       Date:  1992-09-01       Impact factor: 3.857

Review 2.  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer.

Authors:  Ramakrishnan Ayloor Seshadri; Olivier Glehen
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

3.  Photothermally enhanced drug delivery by ultrasmall multifunctional FeCo/graphitic shell nanocrystals.

Authors:  Sarah P Sherlock; Scott M Tabakman; Liming Xie; Hongjie Dai
Journal:  ACS Nano       Date:  2011-02-01       Impact factor: 15.881

4.  Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a clinical practice guideline.

Authors:  R C Auer; D Sivajohanathan; J Biagi; J Conner; E Kennedy; T May
Journal:  Curr Oncol       Date:  2020-06-01       Impact factor: 3.677

5.  Spatiotemporal temperature distribution and cancer cell death in response to extracellular hyperthermia induced by gold nanorods.

Authors:  Huang-Chiao Huang; Kaushal Rege; Jeffrey J Heys
Journal:  ACS Nano       Date:  2010-05-25       Impact factor: 15.881

6.  Surface morphological study of Ehrlich ascites tumor cells exposed to microwave irradiation and heat.

Authors:  E C Chew; D J Riches; T K Lam; H L Hou-Chan
Journal:  Experientia       Date:  1984-08-15

7.  Cooperative nanomaterial system to sensitize, target, and treat tumors.

Authors:  Ji-Ho Park; Geoffrey von Maltzahn; Mary Jue Xu; Valentina Fogal; Venkata Ramana Kotamraju; Erkki Ruoslahti; Sangeeta N Bhatia; Michael J Sailor
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-28       Impact factor: 11.205

8.  Blockage of the hepatic-artery blood flow by biodegradable microspheres (Spherex) combined with local hyperthermia in the treatment of experimental liver tumors in rats.

Authors:  C Erichsen; M Bolmsjö; A Hugander; P E Jönsson
Journal:  J Cancer Res Clin Oncol       Date:  1985       Impact factor: 4.553

9.  Circulatory and metabolic responses of malignant tumors during localized hyperthermia.

Authors:  P Vaupel; K Ostheimer; W Müller-Klieser
Journal:  J Cancer Res Clin Oncol       Date:  1980       Impact factor: 4.553

10.  Whole-body hyperthermia decreases lung metastases in lung tumor-bearing mice, possibly via a mechanism involving natural killer cells.

Authors:  R N Shen; N B Hornback; H Shidnia; R E Shupe; Z Brahmi
Journal:  J Clin Immunol       Date:  1987-05       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.